clinical trial · NCT07551167
A Phase I Study of HRS-5765 in Healthy Participants
Chengdu Suncadia Medicine Co., Ltd.·phase1·not yet recruiting·n = 74
Heart FailureHRS-5765 TabletHRS-5765 Tablet Placebo
brief summary
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of HRS-5765 in healthy participants.
started
Apr 1, 2026
primary completion
Dec 1, 2026
completion
Jan 1, 2027
last updated
Apr 24, 2026
official title
A Randomized, Double-Blind, Dose-Escalation, Placebo-Parallel Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HRS-5765 in Healthy Subjects, as Well as the Effect of Food on the Pharmacokinetics of HRS-5765 and the Effect of HRS-5765 on CYP3A4 Metabolic Enzymes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol